γ-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity

被引：54

作者：

Sako, Kumiko ^{[1
]}

Aoyama, Hiroshi ^{[1
]}

Sato, Shinichi ^{[1
]}

Hashimoto, Yuichi ^{[1
]}

Baba, Masanori ^{[2
]}

机构：

[1] Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Tokyo 1130032, Japan

[2] Kagoshima Univ, Grad Sch Med & Dental Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2008年 / 16卷 / 07期

关键词：

Anti-BVDV agents; gamma-carboline; thalidomide;

D O I：

10.1016/j.bmc.2008.01.052

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Based on anti-viral screening of our heteroaromatics derived from thalidomide, the gamma-carboline skeleton has been identified as a superior scaffold structure for compounds with potent anti-bovine viral diarrhea virus (BVDV) activity. Structural development studies led to a potent anti-viral agent, SK5M (5-methyl-gamma-carboline), with the EC50 of 0.26 mu M. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：3780 / 3790

页数：11

共 20 条

[1]

Baba Chiaki, 2005, Antiviral Chemistry & Chemotherapy, V16, P33

[2] Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents [J].

Bartlett, JB ;

Dredge, K ;

Dalgleish, AG .

NATURE REVIEWS CANCER, 2004, 4 (04) :314-322

[3] Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents [J].

Buckwold, VE ;

Beer, BE ;

Donis, RO .

ANTIVIRAL RESEARCH, 2003, 60 (01) :1-15

[4] Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication [J].

Buckwold, VE ;

Wei, JY ;

Wenzel-Mathers, M ;

Russell, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2293-2298

[5] Etiology and pathogenesis of viral hepatitis [J].

Echevarría-Mayo, JM .

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2006, 24 (01) :45-56

[6] Thalidomide as a multitarget drug and its application as a template for drug design [J].

Hashimoto, Y ;

Tanatani, A ;

Nagasawa, K ;

Miyachi, H .

DRUGS OF THE FUTURE, 2004, 29 (04) :383-391

[7] Structural development of biological response modifiers based on thalidomide [J].

Hashimoto, Y .

BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (03) :461-479

[8]

Hashimoto Y, 1998, CURR MED CHEM, V5, P163

[9] Structural Development of Biological Response Modifiers Based on Retinoids and Thalidomide [J].

Hashimoto, Yuichi .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2002, 2 (06) :543-551

[10] The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis [J].

Hayashi, PH ;

Di Bisceglie, AM .

MEDICAL CLINICS OF NORTH AMERICA, 2005, 89 (02) :371-+

← 1 2 →